Activities of clinical pharmacologists across Europe: A survey by the European association of clinical pharmacology and therapeutics

• Published in: European journal of clinical pharmacology 2024-06, Vol.80 (6), p.919-929
• Main Authors: Marquet, Pierre, Jouanjus, Emilie, Sáez-Peñataro, Joaquin, Sancho-Lopez, Aranzazu
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Drug Monitoring; Drug stores; Europe; Humans; Pharmacogenetics; Pharmacology; Pharmacology, Clinical; Pharmacology/Toxicology; Pharmacovigilance; Surveys; Surveys and Questionnaires; Teaching
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-024-03657-x

Purpose In order to explore clinical pharmacology and therapeutics (CPT) teaching and practices across continental Europe, the European Association of Clinical Pharmacology and Therapeutics (EACPT) made a survey in 2022 amongst its 27 affiliated societies. Methods The survey was made available online to EACPT representatives, and 47 filled-in questionnaires were received from 25 countries (one to five per country), representing all geographic areas of Europe. Results Clinical pharmacologists (CPs) spend 25%, 30%, 15%, and 25% of their time in teaching, hospital activities, committees, and research, respectively, with large variations across and within countries. CPT courses are given at Schools of Medicine in all the countries except one, mostly organized and taught by medical doctors (MDs). In Central, Western, and Southern Europe, the teachers may have medicine or pharmacy training. Therapeutic drug monitoring and pharmacovigilance were the hospital activities most frequently reported, and clinical/forensic toxicology, rounds of visits, and pharmacogenetics the least. Two-thirds of the panel think CPs should be MDs. However, the transversal nature of CPT was underlined, with patients/diseases and drugs as gravity centres, thus calling for the complementary skills of MDs and PharmDs. Besides, most respondents reported that clinical pharmacists in their country are involved in rounds of visits, pharmacovigilance, TDM, and/or pharmacogenetic testing and that collaborations with them would be beneficial. Conclusion CPT comes with a plurality of backgrounds and activities, all required to embrace the different pathologies and the whole lifecycle of medicinal products, but all of them being rarely performed in any given country. The willingness to use common CPT teaching material and prescribing exams at the European level is a good sign of increasing harmonisation of our discipline Europewide.